Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction

Circulation

Volumn 135, Issue 22, 2017, Pages 2085-2087

  Messerli, Franz H ^a,b,c   Bangalore, Sripal ^d  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin converting enzyme inhibitors; hypertension; myocardial infarction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; CLINICAL TRIAL (TOPIC); FEMALE; MALE; PATHOPHYSIOLOGY;

ANGIOTENSIN RECEPTOR ANTAGONISTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION;

EID: 85020042858     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.025950     Document Type: Note

References (5)

1. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE Trial Group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 363 2022 2031. doi: 10.1016/S0140-6736(04)16451-9.
2. Verma S, Strauss M, Angiotensin receptor blockers and myocardial infarction. BMJ 2004 329 1248 1249. doi: 10.1136/bmj.329.7477.1248.
3. Bangalore S, Kumar S, Wetterslev J, Messerli FH, Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011 342 d2234
4. Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH, Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc 2016 91 51 60. doi: 10.1016/j.mayocp.2015.10.019.
5. Bangalore S, Messerli FH, Fraudulent data: an apology and the fate of angiotensin receptor blockers. BMJ 2013 347 f5549